XML 48 R36.htm IDEA: XBRL DOCUMENT v3.25.3
The Company (Details)
$ in Thousands
1 Months Ended 9 Months Ended
Jan. 31, 2025
USD ($)
Sep. 30, 2025
USD ($)
product
Dec. 31, 2024
USD ($)
Collaboration and royalty revenue      
Number of products | product   2  
Accumulated deficit   $ (2,829,264) $ (3,646,873)
License and Collaboration Agreement | Novartis      
Collaboration and royalty revenue      
Cash proceeds from upfront payment on collaboration agreement $ 1,000,000